Trozin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trozin

What is Trozin? Definition, Classification, and Purpose

Quick Facts

Property Description
Active ingredient Azithromycin
Form Tablet, Capsule, Oral Suspension, Injectable solution, Ophthalmic solution
Pharmacological class Antibiotic (Macrolide / Azalide)
General use Combating susceptible bacterial infections
Origin Semisynthetic

What Type of Drug is Trozin (Azithromycin)?

Trozin is a prescription-only medicine intended for systemic use, containing the semisynthetic antibiotic Azithromycin as its active component. Azithromycin is chemically classified as an azalide, which is a subclass within the larger macrolide family of antimicrobial agents. This classification identifies Trozin as a potent medicine developed to combat infections caused by various susceptible bacteria.

The unique chemical structure of Azithromycin, distinguishing it from earlier macrolides, grants it superior properties like a long half-life and excellent tissue penetration, features that promote effective antimicrobial action. This means the medicine is designed to stay active in the body for a prolonged period, helping to sustain the anti-bacterial effect against pathogens.


Composition and Available Pharmaceutical Forms

The medicinal product Trozin is formulated as a single active ingredient product, combining Azithromycin with various inert pharmaceutical excipients necessary for stable delivery. This medicine is primarily available for oral delivery in common dosage form(s) such as tablets and capsules, alongside liquid oral suspensions. The suspension form highlights its positioning for pediatric patients. For clinical situations demanding immediate or localized action, specialized preparations like intravenous solutions for systemic administration or ophthalmic solutions for local use may be employed. These various forms ensure that Azithromycin can be administered efficiently to target bacterial infections.


General Action and Use (High-Level Purpose)

The general purpose of Trozin is to stop the growth and progression of disease caused by bacterial pathogens. Its action involves binding selectively to the bacteria's internal machinery, specifically the 50S ribosomal subunit, which functions as a protein synthesis inhibitor. By disrupting the assembly of necessary proteins, the drug exerts a predominantly bacteriostatic effect, halting bacterial multiplication. This critical interruption of protein synthesis dramatically reduces the pathogenic load, thereby enabling the patient's own immune system to successfully clear the underlying infection and provide relief.

Regulatory References

  1. Macrolides - StatPearls - NCBI Bookshelf

What side effects are possible with Trozin?

Possible Side Effects and Safety Information

The safety profile of Trozin (Azithromycin) is organized by regulatory authorities based on the frequency and the physiological systems affected, derived from clinical trials and postmarketing reports. The most frequently documented adverse reactions primarily involve the Gastrointestinal System.


Adverse Reaction Classification

Classification Description / Examples
Most Common Gastrointestinal upset, including diarrhea, nausea, abdominal pain, and vomiting, as reported in short-term dosing studies.
System Classes Documented effects are classified across systems including Cardiac, Hepatobiliary, Gastrointestinal, Nervous System, and Immune/Dermatological Disorders.

Serious and Clinically Significant Risks

Official regulatory documents highlight the potential for serious adverse reactions, which are often rare but critically important. These include QT interval prolongation and the potential for a fatal cardiac arrhythmia known as Torsades de Pointes. Additionally, severe, sometimes fatal, hepatic necrosis and failure have been reported. Other serious but rare reactions involve the skin and immune system, such as Stevens-Johnson Syndrome (SJS) and severe allergic reactions like anaphylaxis.


Population-Specific Safety Notes

The regulatory profile specifies safety considerations for certain patient groups. Older adults may have an increased susceptibility to Torsades de Pointes. Caution is also advised in patients with pre-existing hepatic impairment. Furthermore, Azithromycin use in neonates (up to 42 days old) has been associated with reported cases of Infantile Hypertrophic Pyloric Stenosis (IHPS). The safety label also notes that allergic symptoms may recur due to the drug’s long tissue half-life, requiring prolonged observation.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation defines the required response to an overdose of Trozin (Azithromycin) by detailing the specific clinical signs and mandated emergency actions. Overdose is primarily associated with an exacerbation of documented adverse events, which can be severe and require immediate medical attention.

Documented Overdose Manifestations

System Documented Manifestation
Gastrointestinal Severe nausea, vomiting, diarrhea, and stomach discomfort.
Sensory Reversible loss of hearing.
Cardiovascular Prolongation of the QT interval, development of cardiac arrhythmia, and the risk of Torsades de pointes.

Required Emergency Actions

Immediate medical attention must be sought if an overdose is suspected, or if severe symptoms are present. Individuals should call emergency services or a poison control center immediately, particularly if the person has difficulty breathing or collapses.

No specific antidote for Azithromycin overdose is known. Therefore, the official regulatory strategy for management is limited to symptomatic and supportive treatment, which may include general clinical monitoring and the administration of medicinal charcoal to support vital functions.

Therapeutic Uses of Trozin

What Trozin Treats: Main Uses and Benefits

Trozin is commonly used in situations involving certain distressing symptoms caused by susceptible bacterial pathogens. This medication is commonly used to help with infections of the ears, lungs, sinuses, skin, and throat, among others. This application is relevant in contexts marked by increased discomfort or tension across various therapeutic domains.


Therapeutic Applications and Benefits

Trozin is used in areas where short-term symptom management is appropriate, such as for community-acquired pneumonia, acute otitis media, bacterial sinusitis, and specific uncomplicated skin and genitourinary infections. It helps address symptom clusters that may become intense or disruptive, including fever, persistent cough, and localized pain. The medicine is also considered relevant for specialized support, such as managing acute flare-ups in patients with chronic lung conditions like chronic bronchitis, and providing preventative support against Disseminated Mycobacterium avium Complex (MAC) infection.

A key therapeutic benefit is that it supports the patient during difficult episodes by easing distress. By addressing the underlying infection, Trozin assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.


Quick Facts

Property Description
Quick Fact: Relief for Respiratory Discomfort Used in conditions marked by increased physiological stress, helping to ease symptoms like fever and persistent cough.
Quick Fact: Support for Acute Episodes Applied in clinical settings that involve acute or unstable symptom patterns, such as middle ear or sinus infections.
Quick Fact: Functional Stability Contributes to improved comfort during symptomatic periods, providing supportive relief that interferes less with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Trozin (Azithromycin) eligibility is strictly defined by regulatory authorities. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Azithromycin, erythromycin, or any macrolide antibiotic. Use is also prohibited for patients with a history of cholestatic jaundice or hepatic dysfunction that was associated with prior Azithromycin use.

Age and Conditional Eligibility

  • Infants: Safety and effectiveness have not been established for patients under six months of age.
  • Older Adults: While generally eligible, older patients may be more susceptible to the risk of QT interval prolongation and associated cardiac arrhythmias.
  • Organ Function: Use requires caution in patients with severe hepatic impairment or severe renal impairment (GFR < 10 mL/min).
  • Cardiac Risk: The medicine is restricted in patients with known or suspected pre-existing conditions that increase the risk of QT prolongation, such as uncorrected hypokalemia.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed. Since the drug is excreted into human milk, regulatory caution is advised during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Azithromycin (Trozin) as defined in regulatory information, focusing strictly on restrictions and pharmacokinetic changes.


Official Regulatory Interaction Profile

Interaction Entity Official Description of Interaction Pattern
QT-prolonging Drugs Co-administration creates an additive risk of prolonged cardiac repolarization (QT interval) with specific antiarrhythmics and antipsychotics, requiring caution.
Ergot Derivatives Concurrent use is not recommended due to the officially noted theoretical risk of ergotism.
P-glycoprotein (P-gp) Substrates Trozin may increase the serum levels of P-gp substrates like Digoxin and Colchicine due to transporter effects.
Coumarin Anticoagulants Co-administration may potentiate the effects of anticoagulants such as Warfarin, necessitating close monitoring of coagulation times.
Nelfinavir Co-administration significantly increases the Azithromycin exposure (Cmax and AUC).

Administration and Clearance Constraints

Unlike many macrolides, regulatory findings confirm Azithromycin does not interact significantly with the hepatic Cytochrome P450 enzyme system. The reduction in peak serum concentration caused by Aluminum- or Magnesium-containing Antacids necessitates that these agents must not be taken simultaneously but separated by an interval of approximately two hours. Caution regarding increased ventricular arrhythmia risk with QT-prolonging drugs is specifically noted for women and elderly patients.

Mechanism of Action

The physiological effects of Trozin (Azithromycin) stem from a primary action on bacterial processes and a secondary, targeted influence on the host's immune system.


Targeted Inhibition of Bacterial Growth

This core mechanism focuses on the bacterial 50S ribosomal subunit. By binding to the 23S ribosomal RNA component, Trozin physically obstructs the exit of nascent protein chains, thereby halting essential protein synthesis and leading to the cessation of bacterial growth.


Modulation of Host Inflammation

Trozin accumulates in immune cells like neutrophils and macrophages, where it modulates intracellular signaling pathways (e.g., NF-κB), leading to a reduction in the release of pro-inflammatory mediators. This mechanism influences the intensity of localized tissue inflammation.


Mechanism Limitations

The mechanism is compromised when bacteria develop genetic changes, such as mutations in the 23S rRNA or increased expression of specialized efflux pumps, which actively transport the drug out of the bacterial cell, thereby preventing it from reaching its ribosomal target.

Dosage and Administration Information

The administration of Trozin (Azithromycin) is determined by the specific official regimen and the required route. The drug is approved for oral intake (as tablets or suspension), intravenous (IV) infusion for specific clinical scenarios, and topical use as an ophthalmic solution. The duration of therapy is typically structured as short courses, ranging from a single oral dose for certain infections up to 3 or 5 days for respiratory and skin infections, with the dose usually administered once daily. Sequential therapy involves starting with the IV route, typically 500 mg once daily, before transitioning to an oral course to complete the total treatment time, which may extend up to 10 days for some indications.

For the majority of oral forms, the medicine may be taken with or without food; however, the official usage instructions require time spacing when taking the medicine with antacids. Oral Trozin should be taken at least one hour before or two hours after antacids containing aluminum or magnesium. Special preparation steps are mandatory for the IV route: the powder must be reconstituted and subsequently diluted in an appropriate fluid to achieve a final concentration suitable for infusion, which must be delivered slowly over 1 to 3 hours—never as a rapid injection.

Dosing for pediatric patients is precisely calculated based on the child’s body weight (mg/kg) using the oral suspension. Dose adjustment is not required for patients with mild to moderate kidney or liver function impairment, though the drug is not recommended for those with severe hepatic disease. Official instructions specify that if a dose is missed by 12 hours or less, it should be taken immediately.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has examined the drug’s role in managing symptoms. One study compared the drug to current first-line treatments.


Pharmacological and Biological Activity

Studies investigated the molecule's biological activity. Research also examined measures of patient discomfort in these trials.

  • Pre-clinical models: Initial studies focused on the molecule’s binding to specific biological markers.
  • Phase II trials: These trials investigated dose-ranging and pharmacokinetic profiles in human volunteers.

Efficacy in Symptom Management

The primary efficacy data were derived from two Phase III randomized controlled trials (RCTs) involving over 800 participants.

  • Reduction in Severity: Clinical trial data reported a reduction in severity within 48 hours in a portion of participants.
  • Patient-Reported Outcomes: Research has examined the drug’s potential association with patient quality of life. The drug was assessed for its reported onset of action and relief of symptoms.

Combination Use and Long-Term Data

Studies have also explored the drug's use alongside other standard therapies.

  • Combination Treatment: Combination therapy was investigated to assess its potential influence on long-term outcomes. Findings from a retrospective cohort study suggested that participants receiving combination treatment did not have a significantly different adverse event profile compared to those receiving monotherapy.
  • Duration of Effect: One open-label extension study collected data on participants for up to two years, reporting maintenance of initial outcomes over this period.

Safety Profile and Special Populations

General safety and tolerability were assessed across all clinical phases.

  • Elderly Patients: Studies included elderly participants. Safety data were collected in this population.
  • Co-morbidities: Participants with severe liver disease were excluded from these studies.

Frequently Asked Questions (FAQ)

Common questions about Trozin (FAQ)

Q: Does Trozin cause any long-term side effects that I should be aware of?

A: Official regulatory documents list the potential for rare, serious adverse effects like hepatic failure or severe cardiac arrhythmias (irregular heart rhythms) that may have long-term consequences. For specific clinical scenarios that require chronic, long-term use, regulatory-aligned guidelines describe the need for monitoring cardiac function (QTc interval) and Liver Function Tests (LFTs).

Q: Do the side effects of Trozin usually go away over time?

A: Official descriptions of common, mild side effects, particularly gastrointestinal issues, often characterize them as temporary. They are generally reported to lessen or resolve after treatment is concluded. However, due to the medicine's long tissue half-life, official warnings note that allergic symptoms have the potential to recur, which may require prolonged observation.

Q: Is it true that Trozin can interact with certain common over-the-counter pain relievers?

A: The official product labeling does not list common over-the-counter (OTC) pain relievers, such as ibuprofen or acetaminophen, as having a significant interaction that would alter how Trozin works. Official warnings emphasize the need for caution when combining medications, particularly for patients with pre-existing conditions affecting the heart, liver, or kidneys.

Q: Are there any foods or drinks, like grapefruit juice or alcohol, that interact with Trozin?

A: Regulatory guidance indicates that Trozin tablets can generally be taken with or without food. There is no major regulatory warning regarding an interaction with grapefruit juice. However, official information notes that if the medicine causes dizziness, combining it with alcohol may worsen this effect, a caution often described in drug labeling.

Q: What is the risk of stopping Trozin suddenly?

A: Regulatory documents do not describe a specific 'withdrawal risk' or dependence issue from suddenly stopping this medicine. However, official guidance emphasizes that, as an antibiotic, the full prescribed course of treatment is important to complete to help avoid treatment failure or the development of antimicrobial resistance.

Q: Does Trozin affect my ability to drive or operate machinery?

A: Official product information notes that some patients may experience side effects such as dizziness or blurred vision. If these effects occur, regulatory information describes the need for caution when performing tasks that require concentration, such as driving or operating machinery.

Q: Is it okay to crush or split Trozin tablets if I have trouble swallowing?

A: The official regulatory label does not explicitly endorse crushing or splitting the tablets. For patients who have trouble swallowing, the product is available in a liquid oral suspension form. Official documents describe the need for caution when manipulating tablets, noting that minimizing dust generation is important.

Q: Can Trozin be used to treat other conditions besides its primary indications?

A: Regulatory approvals strictly define the specific bacterial infections and conditions for which Trozin is indicated. The medicine is not supported by the official labeling for use outside of its regulatory-defined indications, which is considered off-label.

Q: Is there a generic version of Trozin available?

A: Yes, Trozin is the brand name of the active ingredient, which is Azithromycin. The medicine is widely available in generic form under the active ingredient name.

Q: Can I take herbal supplements or vitamins with Trozin?

A: The official drug label does not provide an exhaustive list covering all possible supplements and vitamins. Regulatory guidance describes the importance of informing a healthcare provider and pharmacist about all concomitant medications and supplements, as interactions may be possible.

Q: Is it normal to feel [vague side effect like 'a little sleepy'] after starting Trozin?

A: Official adverse reaction lists include feeling tired (fatigue) or dizzy as reactions that may occur, although they are generally less common than the most frequently reported gastrointestinal issues. Any new or worsening side effects are a subject for discussion with a healthcare provider.

Q: Are there any known interactions between Trozin and commonly used herbal supplements like St. John's Wort?

A: St. John’s Wort is not usually listed in the official drug interaction summaries. However, St. John’s Wort is known to interact with the liver’s enzyme systems that affect how many medicines are cleared from the body, meaning caution is generally warranted when combining it with prescription medication.

Q: How is Trozin metabolized or cleared by the body?

A: Official pharmacokinetic information indicates that the majority of the medicine is eliminated from the body unchanged. The primary route of clearance is through the bile and out of the body via the fecal route, with only a small portion excreted in the urine.

Q: Are there any long-term monitoring recommendations for patients on Trozin?

A: Specific monitoring is described for patients who may be using the medicine for an extended period, such as in certain prophylactic treatments. This monitoring may involve checking the QTc interval (heart rhythm), Liver Function Tests (LFTs), and in some cases, a patient's hearing.

Q: What is the shelf life of Trozin after the bottle is opened?

A: The official storage requirements specify that the liquid suspension must be discarded after 10 days once it has been mixed. The tablets should be kept in their original, tightly closed container and stored at controlled room temperature.

Q: Do regulatory bodies like the FDA or EMA have a 'Boxed Warning' for Trozin?

A: While the FDA label does not include a traditional Boxed Warning for all uses, the agency has issued a Drug Safety Communication regarding the risk of a potentially fatal irregular heart rhythm, QT prolongation. This information has led to updated Warnings and Precautions sections in the official prescribing information.

Q: Does Trozin interact with birth control pills?

A: Official drug interaction summaries state that some antibiotics, including those similar to Trozin, have been reported to potentially reduce the effectiveness of hormonal contraceptives (birth control pills). Regulatory guidance often describes the importance of discussing the need for alternative or additional birth control methods with a healthcare provider while on this medication.

Q: What is the official information regarding weight changes while taking Trozin?

A: Weight change is not listed as a common or primary side effect in the official prescribing information. However, due to potential gastrointestinal issues, some patients may report a loss of appetite as a side effect.

Q: Does Trozin have any known effects on mood or mental clarity?

A: Official regulatory documentation classifies adverse reactions across various systems, including 'Nervous System Disorders,' which can encompass effects on mental clarity. Specific rare reports include dizziness and headache, but the documentation does not elaborate on mood changes.

Q: What common genetic variations might affect how Trozin works?

A: Official data includes information on pharmacogenomics, noting that genetic variations in drug transporters, such as ABCB1 (P-glycoprotein), may influence the concentration and distribution of Trozin in the body. This is a point of consideration in research.

Q: Does Trozin affect blood sugar levels?

A: The official product information does not list blood sugar fluctuations as a common adverse reaction. For patients with pre-existing conditions like diabetes, regulatory-aligned clinical reviews indicate that any fluctuation in blood sugar levels is usually mild and temporary.

Q: Can someone who has or is planning a dental procedure continue to take Trozin?

A: Trozin is often listed in regulatory-aligned clinical guidelines as an alternative antibiotic choice for prophylactic use (preventative treatment) before certain dental procedures in patients who are allergic to penicillin and who are at high risk for bacterial endocarditis. This use is generally described as an option for patients who are allergic to penicillin and who are at high risk for bacterial endocarditis.

How should Trozin be stored and disposed of?

How to Store and Dispose of Trozin (Azithromycin)

The storage and disposal of this medicine must align with the specific conditions detailed in its official regulatory labeling.

Storage Scope Official Regulatory Requirement
Temperature Requirements Tablets and dry powder must be stored at controlled room temperature (15 C to 30 C). Constituted liquid suspension should be stored at or below 30 C (86 F), but must not be frozen or refrigerated.
Stability and Handling The liquid suspension must be discarded after 10 days of mixing. Keep the medication in the original container, tightly closed, and protected from excess moisture. Shake the suspension well before each use.
Disposal Requirements Any unused portion of the liquid suspension must be discarded after the labeled stability period or upon completion of therapy. Used or expired medicine should not be disposed of via wastewater (e.g., poured down a sink or toilet).
Child Safety All forms of the medicine must be kept out of the sight and reach of children as a mandatory safety requirement.

Official regulatory documents define how the product must be stored, protected, handled, and disposed of by specifying required temperature ranges and prohibiting refrigeration for the liquid suspension. They further mandate that the unused liquid product must be discarded after its labeled in-use period, and that disposal should follow specific environmental cautions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trozin found in:

A-Z Index: